MedMira Inc News

Clinical Trials to Get Underway With Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada

AccesswireAug 13 16:30 ET

MedMira Reports Third Quarter Results FY2024

AccesswireJul 2 23:00 ET

MedMira Announces the Hire of Vice President of Business Development

AccesswireApr 30 22:00 ET

Medmira Inc. Expands U.S. Presence Amidst Losses

TipRanksApr 1 23:07 ET

MedMira Reports Second Quarter Results FY2024

AccesswireApr 1 22:30 ET

MedMira Receives Canadian Patent for Its Unique Quantitative Diagnostic System

AccesswireMar 13 16:30 ET

Corporate Update on Clinical Evaluation of MedMira's Products

AccesswireFeb 1 07:35 ET

MedMira's Fiscal Q1 Loss Widens, Revenue Drops

MT NewswiresJan 2 10:15 ET

MedMira Reports First Quarter Results FY2024

Stockhouse Dec 29, 2023 23:00 ET

U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test

AccesswireDec 13, 2023 22:30 ET

MedMira Reports FY2023 Fourth Quarter and Year End Financial Results

AccesswireNov 28, 2023 23:00 ET

Progress Update on Securities

AccesswireAug 30, 2023 22:00 ET

TSX Venture Exchange Stock Maintenance Bulletins

Stockhouse Aug 29, 2023 22:00 ET

Canadian Investment Regulatory Organization Trading Halt - MIR

Stockhouse Aug 29, 2023 10:49 ET

MedMira Inc. GAAP EPS of C$0.00

Seeking AlphaJun 30, 2023 14:29 ET

MedMira Reports Third Quarter Results FY2023

AccesswireJun 29, 2023 22:00 ET

MedMira Reports Second Quarter Results FY2023

AccesswireApr 3, 2023 21:00 ET

Update on MedMira's Reveal TP (Syphilis) Clinical Trials in Canada

AccesswireMar 14, 2023 16:35 ET

MedMira Enters Into Partnership With Maternova for USA and Latin America

AccesswireFeb 20, 2023 17:02 ET

MedMira Reports First Quarter Results FY2023

AccesswireDec 30, 2022 22:06 ET